The Role of Bronchoalveolar Hemostasis in the Pathogenesis of Acute Lung Injury

Jorrit–Jan H. Hofstra; Jack J. Haitsma; Nicole P. Juffermans; Marcel Levi; Marcus J. Schultz

doi:10.1055/s-0028-1092878

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2008; 34(5): 475-484
DOI: 10.1055/s-0028-1092878

The Role of Bronchoalveolar Hemostasis in the Pathogenesis of Acute Lung Injury

Jorrit–Jan H. Hofstra¹ ^, ² , Jack J. Haitsma⁵ , Nicole P. Juffermans¹ ^, ² , Marcel Levi³ , Marcus J. Schultz¹ ^, ² ^, ⁴

¹Department of Intensive Care Medicine, Amsterdam, The Netherlands
²Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam, The Netherlands
³Department of Internal Medicine, Amsterdam, The Netherlands
⁴HERMES Critical Care Group, Amsterdam, The Netherlands
⁵Interdepartmental Division of Critical Care, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

Abstract

ABSTRACT

Disturbed alveolar fibrin turnover is intrinsic to acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and pneumonia and is important to its pathogenesis. Recent studies also suggest disturbed alveolar fibrin turnover to be a feature of ventilator-induced lung injury (VILI). The mechanisms that contribute to alveolar coagulopathy are localized tissue factor–mediated thrombin generation, impaired activity of natural coagulation inhibitors, and depression of bronchoalveolar urokinase plasminogen activator–mediated fibrinolysis, caused by the increase of plasminogen activator inhibitors. Administration of anticoagulant agents (including activated protein C, antithrombin, tissue factor–factor VIIa pathway inhibitors, and heparin) and profibrinolytic agents (including plasminogen activators) attenuate pulmonary coagulopathy. Several preclinical studies show additional anti-inflammatory effects of these therapies in ALI/ARDS and pneumonia. In this article, we review the involvement of coagulation and fibrinolysis in the pathogenesis of ALI/ARDS pneumonia and VILI and the potential of anticoagulant and profibrinolytic strategies to reverse pulmonary coagulopathy and pulmonary inflammatory responses.

KEYWORDS

Acute lung injury - acute respiratory distress syndrome - coagulation - fibrinolysis

Volltext

Referenzen

REFERENCES

1 Bernard G R, Artigas A, Brigham K L et al.. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149 818-824
2 Davis K A. Ventilator-associated pneumonia: a review. J Intensive Care Med. 2006; 21 211-226
3 Dos Santos C C, Slutsky A S. Invited review: mechanisms of ventilator-induced lung injury: a perspective. J Appl Physiol. 2000; 89 1645-1655
4 Levi M, Ten C H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341 586-592
5 Schultz M J, Haitsma J J, Zhang H, Slutsky A S. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review. Crit Care Med. 2006; 34 871-877
6 Dahlem P, Bos A P, Haitsma J J, Schultz M J, Meijers J C, Lachmann B. Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med. 2005; 31 724-732
7 Dahlem P, Bos A P, Haitsma J J et al.. Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. Eur Respir J. 2006; 28 992-998
8 Welty-Wolf K E, Carraway M S, Ortel T L, Piantadosi C A. Coagulation and inflammation in acute lung injury. Thromb Haemost. 2002; 88 17-25
9 Biemond B J, Levi M, Ten C H et al.. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost. 1995; 73 223-230
10 Levi M, Ten C H, Bauer K A et al.. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994; 93 114-120
11 Levi M, Schultz M J, Rijneveld A W. van der PT. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med. 2003; 31 S238-S242
12 Fourrier F, Chopin C, Goudemand J et al.. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992; 101 816-823
13 Faust S N, Levin M, Harrison O B et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001; 345 408-416
14 Moore K L, Esmon C T, Esmon N L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989; 73 159-165
15 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986; 163 740-745
16 Sawdey M S, Loskutoff D J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991; 88 1346-1353
17 Abraham E, Reinhart K, Svoboda P et al.. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001; 29 2081-2089
18 Eisele B, Lamy M, Thijs L G et al.. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998; 24 663-672
19 Warren B L, Eid A, Singer P et al.. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286 1869-1878
20 Abraham E, Reinhart K, Opal S et al.. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290 238-247
21 Bernard G R, Vincent J L, Laterre P F et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344 699-709
22 Dellinger R P, Carlet J M, Masur H et al.. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004; 30 536-555
23 Gunther A, Mosavi P, Heinemann S et al.. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000; 161 454-462
24 Idell S, Gonzalez K, Bradford H et al.. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir Dis. 1987; 136 1466-1474
25 Idell S, Koenig K B, Fair D S, Martin T R, McLarty J, Maunder R J. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol. 1991; 261 L240-L248
26 Fuchs-Buder T, de Moerloose P, Ricou B et al.. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996; 153 163-167
27 Miller D L, Welty-Wolf K, Carraway M S et al.. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol. 2002; 26 650-658
28 Ware L B, Fang X, Matthay M A. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003; 285 L514-L521
29 Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis. 1998; 9(Suppl 2) S25-S37
30 de Moerlosse P, De Benedetti E, Nicod L, Vifian C, Reber G. Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res. 1992; 65 507-518
31 Idell S. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med. 2002; 30 S274-S280
32 Marshall B C, Sageser D S, Rao N V, Emi M, Hoidal J R. Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem. 1990; 265 8198-8204
33 Prabhakaran P, Ware L B, White K E, Cross M T, Matthay M A, Olman M A. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003; 285 L20-L28
34 Wygrecka M, Markart P, Ruppert C et al.. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J. 2007; 29 1105-1114
35 Chapman H A, Stahl M, Allen C L, Yee R, Fair D S. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis. 1988; 137 1417-1425
36 Levi M, van Der P OLL, Ten C H et al.. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med. 1998; 158 92-98
37 Chapman H A, Yang X L, Sailor L Z, Sugarbaker D J. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. J Immunol. 1990; 145 3398-3405
38 Boutten A, Dehoux M S, Seta N et al.. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1996; 153 336-342
39 Dehoux M S, Boutten A, Ostinelli J et al.. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1994; 150 710-716
40 Millo J L, Schultz M J, Williams C et al.. Compartmentalization of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med. 2004; 30 68-74
41 Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol. 2000; 22 401-404
42 Schultz M J, Millo J, Levi M et al.. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax. 2004; 59 130-135
43 Drake T A, Morrissey J H, Edgington T S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134 1087-1097
44 Altieri D C. Inflammatory cell participation in coagulation. Semin Cell Biol. 1995; 6 269-274
45 Chapman H A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997; 9 714-724
46 Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler. 1991; 372 1007-1013
47 Choi G, Schultz M J, Levi M, van der P T, Millo J L, Garrard C S. Protein C in pneumonia. Thorax. 2005; 60 705-706
48 Choi G, Wolthuis E K, Bresser P et al.. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology. 2006; 105 689-695
49 van der P T, Levi M, Nick J A, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med. 2005; 171 1125-1128
50 Choi G, Hofstra J J, Roelofs J J et al.. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med. 2007; 35 1362-1368
51 Choi G, Hofstra J J, Roelofs J J et al.. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med. 2008; 36 204-210
52 Altemeier W A, Matute-Bello G, Frevert C W et al.. Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin. Am J Physiol Lung Cell Mol Physiol. 2004; 287 L533-L542
53 Belperio J A, Keane M P, Burdick M D et al.. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest. 2002; 110 1703-1716
54 Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000; 342 1301-1308
55 Ranieri V M, Suter P M, Tortorella C et al.. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999; 282 54-61
56 Wolthuis E K, Choi G, Dessing M C et al.. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents pulmonary inflammation in patients without preexisting lung injury. Anesthesiology. 2008; 108 46-54
57 Haitsma J J, Wolthuis E K, Schultz M J, Levi M, Zhang H, Slutsky A S. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Presented at: Annual Meeting of the American Thoracic Society May 20, 2007 San Francisco, CA;
58 Coughlin S R. Thrombin signalling and protease-activated receptors. Nature. 2000; 407 258-264
59 Levi M, van der P T, Ten C H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost. 2006; 32 33-39
60 Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem. 2000; 275 6580-6585
61 Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 1998; 91 2698-2703
62 Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005; 109 227-241
63 Cunningham M A, Romas P, Hutchinson P, Holdsworth S R, Tipping P G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood. 1999; 94 3413-3420
64 Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol. 1998; 160 5130-5135
65 Johnson K, Aarden L, Choi Y, De G E, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood. 1996; 87 5051-5060
66 Sower L E, Froelich C J, Carney D H, Fenton J W, Klimpel G R. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol. 1995; 155 895-901
67 Huang J S, Ramamurthy S K, Lin X, Le Breton G C. Cell signalling through thromboxane A2 receptors. Cell Signal. 2004; 16 521-533
68 Ruggeri Z M. Platelets in atherothrombosis. Nat Med. 2002; 8 1227-1234
69 Goff C D, Corbin R S, Theiss S D et al.. Postinjury thromboxane receptor blockade ameliorates acute lung injury. Ann Thorac Surg. 1997; 64 826-829
70 Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006; 116 3211-3219
71 Pitchford S C, Momi S, Giannini S et al.. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood. 2005; 105 2074-2081
72 Carvalho-Tavares J, Hickey M J, Hutchison J, Michaud J, Sutcliffe I T, Kubes P. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res. 2000; 87 1141-1148
73 Drew A F, Liu H, Davidson J M, Daugherty C C, Degen J L. Wound-healing defects in mice lacking fibrinogen. Blood. 2001; 97 3691-3698
74 Perez R L, Ritzenthaler J D, Roman J. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol. 1999; 20 1059-1066
75 Roman J, Ritzenthaler J D, Perez R L, Roser S L. Differential modes of regulation of interleukin-1beta expression by extracellular matrices. Immunology. 1999; 98 228-237
76 Sitrin R G, Pan P M, Srikanth S, Todd III R F. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol. 1998; 161 1462-1470
77 Idell S, James K K, Levin E G et al.. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest. 1989; 84 695-705
78 Seeger W, Stohr G, Wolf H R, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol. 1985; 58 326-338
79 Seeger W, Gunther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol. 1992; 262 L286-L291
80 Esmon C T. The protein C pathway. Chest. 2003; 124 26S-32S
81 Yasui H, Gabazza E C, Tamaki S et al.. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med. 2001; 163 1660-1668
82 Murakami K, Okajima K, Uchiba M et al.. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996; 87 642-647
83 Murakami K, Okajima K, Uchiba M et al.. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol. 1997; 272 L197-L202
84 Slofstra S H, Groot A P, Maris N A, Reitsma P H, Cate H T, Spek C A. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol. 2006; 149 740-746
85a Kotanidou A, Loutrari H, Papadomichelakis E et al.. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol. 2006; 45 134-140
85b Liu K D, Levitt J, Zhuo H et al.. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008; 178 618-623
86 Welty-Wolf K E, Carraway M S, Miller D L et al.. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med. 2001; 164 1988-1996
87 Welty-Wolf K E, Carraway M S, Ortel T L et al.. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol. 2006; 290 L21-L31
88 Enkhbaatar P, Okajima K, Uchiba M, Isobe H, Okabe H. Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb Haemost. 2001; 86 1573-1577
89 Creasey A A, Chang A C, Feigen L, Wun T C, Taylor Jr F B, Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993; 91 2850-2860
90 Carraway M S, Welty-Wolf K E, Miller D L et al.. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med. 2003; 167 1200-1209
91 Opal S M, Palardy J E, Parejo N A, Creasey A A. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med. 2001; 29 13-17
92 Enkhbaatar P, Okajima K, Murakami K et al.. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med. 2000; 162 1752-1759
93 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res. 1990; 59 895-904
94 Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun. 1989; 163 1404-1411
95 Oelschlager C, Romisch J, Staubitz A et al.. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood. 2002; 99 4015-4020
96 Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood. 1999; 93 157-164
97 Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol. 1990; 39 477-484
98 Kaneider N C, Egger P, Dunzendorfer S, Wiedermann C J. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun. 2001; 287 42-46
99 Ostrovsky L, Woodman R C, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 1997; 96 2302-2310
100 Duensing T D, Wing J S, van Putten J P. Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun. 1999; 67 4463-4468
101 Kipnis E, Guery B P, Tournoys A et al.. Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock. 2004; 21 444-451
102 Hochart H, Jenkins P V, Smith O P, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol. 2006; 133 62-67
103 Lever R, Page C P. Novel drug development opportunities for heparin. Nat Rev Drug Discov. 2002; 1 140-148
104 Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996; 270 L921-L930
105 Schiffer E R, Reber G, de M P, Morel D R. Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med. 2002; 30 2689-2699
106 Darien B J, Fareed J, Centgraf K S et al.. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock. 1998; 9 274-281
107 Slofstra S H, van't Veer C, Buurman W A, Reitsma P H, ten Cate H, Spek C A. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med. 2005; 33 1365-1370
108 Cox Jr C S, Zwischenberger J B, Traber D L, Traber L D, Haque A K, Herndon D N. Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet. 1993; 176 339-349
109 Murakami K, McGuire R, Cox R A et al.. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock. 2002; 18 236-241
110 Stringer K A, Lindenfeld J, Repine A J, Cohen Z, Repine J E. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation. 1997; 21 27-34
111 Abraham E, Gyetko M R, Kuhn K et al.. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol. 2003; 170 5644-5651
112 Hardaway R M, Williams C H, Marvasti M et al.. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med. 1990; 18 1413-1418
113 Stringer K A, Hybertson B M, Cho O J, Cohen Z, Repine J E. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med. 1998; 25 184-188
114 Choi G, Vlaar A P, Schouten M et al.. Natural anticoagulants limit LPS-induced pulmonary coagulation but not inflammation. Eur Respir J. 2007; 30 423-428
115 Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003; 31 S213-S220
116 MacLaren R, Stringer K A. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy. 2007; 27 860-873
117 Ware L B, Bastarache J A, Wang L. Coagulation and fibrinolysis in human acute lung injury—new therapeutic targets?. Keio J Med. 2005; 54 142-149
118 Ware L B, Camerer E, Welty-Wolf K, Schultz M J, Matthay M A. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2006; 291 L307-L311
119 Laterre P F, Garber G, Levy H et al.. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med. 2005; 33 952-961
120 Lahteenmaki K, Kuusela P, Korhonen T K. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev. 2001; 25 531-552
121 Robriquet L, Collet F, Tournoys A et al.. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res. 2006; 7 41
122 ISRCTN52566874 . Activated protein C versus placebo in the treatment of inflammatory or infectious ALI/ARDS (INFALI): a pathophysiological study on pulmonary microvascular permeability, apoptosis, inflammation and coagulation. 2007;
123 Seeger W, Hubel J, Klapettek K et al.. Procoagulant activity in bronchoalveolar lavage of severely traumatized patients–relation to the development of acute respiratory distress. Thromb Res. 1991; 61 53-64
124 Gunther A, Kalinowski M, Elssner A, Seeger W. Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity. Am J Physiol. 1994; 267 L618-L624

Jorrit–Jan H HofstraM.D.

Department of Intensive Care Medicine, Academic Medical Center

University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

eMail: j.j.hofstra@amc.uva.nl